SURVYR

CAPR

Capricor Therapeutics, Inc.
$6.10
+$0.36 (6.27%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-52%+79%+210%+341%+472%Oct 2025Oct 2026Apr 202652w low $2.96
CAPRSPY
Wall St. Highest PT $54.00 (+785.2%) Wall St. Avg PT $27.00 (+342.6%)
$4$21$39$56$74POC $30Hi $54Avg $27
Underwater Drawdown %Max DD -89.1%Current -82.7%
0.0%-89.1%
Relative Strength vs SPY-14.8% vs SPYUnderperforming
+539%0%-539%
1W
−$0.51 (7.72%)
1M
−$2.26 (27.03%)
3M
−$0.47 (7.15%)
6M
−$27.88 (82.05%)
YTD
−$22.76 (78.86%)
1Y
−$0.08 (1.29%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
5 analysts · mean score 2.30
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$6.10
Average target$27.00
+$20.90 (+342.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$7.00
Median$27.00
High$54.00
12-month Wall Street target range
Recent analyst rating changes · 30
Upgrade
2026-09-14 · B. Riley Securities upgraded CAPR from Neutral to Buy
Upgrade
2026-09-01 · Piper Sandler upgraded CAPR from Neutral to Overweight
Upgrade
2026-08-14 · Cantor Fitzgerald upgraded CAPR from Neutral to Overweight
Downgrade
2026-07-31 · Jones Trading downgraded CAPR from Buy to Hold
Downgrade
2026-07-30 · Piper Sandler downgraded CAPR from Overweight to Neutral
Downgrade
2026-07-30 · Cantor Fitzgerald downgraded CAPR from Overweight to Neutral
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$344.8M
P/E (next 12 months, estimated)-4.1
52-week range$2.96 – $40.37
Dividend yieldNo dividend
Analyst consensusBuy (5)
Average analyst price target$27.00 (+343%)

What they do

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for CAPR yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

CAPR earningsNext report in 13 days
Next report
Tue Nov 10, 2026Time not confirmed
EPS consensus-$0.41 range -$0.74–$0.87
Revenue consensus$10.4M 9 analysts
Last 4 quarters · EPS vs estimate
Aug 13, 2026-$0.70est -$0.58−21.6%Below estimates
Mar 12, 2026-$0.62est -$0.55−12.4%Below estimates
Nov 10, 2025-$0.54est -$0.54+0.3%In line with estimates
Aug 11, 2025-$0.57est -$0.48−19.4%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 08:44:30 ET
24-0824-1125-0325-0525-0825-1126-0326-08-0.700.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears
Stocktwits · Oct 21
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
Stocktwits · Oct 07
Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
MarketBeat · Oct 07
Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
Stocktwits · Oct 05
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
GlobeNewswire · Oct 05
Rating changes
Upgrade
2026-09-14 · B. Riley Securities upgraded CAPR from Neutral to Buy
Upgrade
2026-09-01 · Piper Sandler upgraded CAPR from Neutral to Overweight
Upgrade
2026-08-14 · Cantor Fitzgerald upgraded CAPR from Neutral to Overweight
Downgrade
2026-07-31 · Jones Trading downgraded CAPR from Buy to Hold
Downgrade
2026-07-30 · Piper Sandler downgraded CAPR from Overweight to Neutral
Downgrade
2026-07-30 · Cantor Fitzgerald downgraded CAPR from Overweight to Neutral

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-24 08:44:30 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026